| Designed ankyrin repeat proteins (DARPins): from research to therapy R Tamaskovic, M Simon, N Stefan, M Schwill, A Plückthun Methods in enzymology 503, 101-134, 2012 | 165 | 2012 |
| Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2 C Jost, J Schilling, R Tamaskovic, M Schwill, A Honegger, A Plückthun Structure 21 (11), 1979-1991, 2013 | 163 | 2013 |
| Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS–p110 crosstalk R Tamaskovic, M Schwill, G Nagy-Davidescu, C Jost, DC Schaefer, ... Nature Communications 7 (1), 11672, 2016 | 48 | 2016 |
| Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action F Kast, M Schwill, JC Stüber, S Pfundstein, G Nagy-Davidescu, ... Nature Communications 12 (1), 3790, 2021 | 44 | 2021 |
| Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer M Schwill, R Tamaskovic, AS Gajadhar, F Kast, FM White, A Plückthun Science signaling 12 (565), eaau2875, 2019 | 42 | 2019 |
| Bispecific HER2 ligands for cancer therapy R Tamaskovic, M Schwill, A Pluckthun, C Jost US Patent 10,093,740, 2018 | 29* | 2018 |
| Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization JC Stüber, CP Richter, JS Bellón, M Schwill, I König, B Schuler, J Piehler, ... Communications Biology 4 (1), 762, 2021 | 14 | 2021 |
| High-throughput generation of bispecific binding proteins by Sortase A–mediated coupling for direct functional screening in Cell Culture F Andres, M Schwill, YL Boersma, A Plückthun Molecular cancer therapeutics 19 (4), 1080-1088, 2020 | 11 | 2020 |
| Bispecific HER2 Ligands for Cancer Therapy A Plückthun, F Kast, M Schwill, A Honegger, R Tamaskovic, C Jost US Patent App. 17/577,055, 2022 | | 2022 |
| Her2-binding tetrameric polypeptides F Kast, M Schwill, A Honegger, J Stüber, R Tamaskovic, A Plückthun US Patent App. 17/282,781, 2021 | | 2021 |
| Bispecific HER2 Ligands for Cancer Therapy A Plückthun, F Kast, M Schwill, A Honegger, R Tamaskovic, C Jost US Patent App. 16/153,857, 2019 | | 2019 |
| Biparatopic DARPins for Anti-ErbB2 Therapy: Intermolecular Trapping of ErbB2/HER2 Receptor Induces pan-ErbB Inhibition and Overcomes the Signaling Robustness in ErbB2-Dependent … M Schwill University of Zurich, 2017 | | 2017 |
| Targeting ErbB2 Receptor and Analysis of ErbB2-driven Oncogenic Networks M Schwill Universität Zürich, 2017 | | 2017 |
| Bispecific her2 ligands for cancer therapy R Tamaskovic, M Schwill, A Plückthun, C Jost | | 2014 |